AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, strengthening its haematological cancer pipeline
AstraZeneca announces an agreement to acquire TeneoTwo, Inc., including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma1.
AstraZeneca’s Pascal Soriot awarded British knighthood for services to UK life sciences and leadership in the global response to the COVID pandemic
AstraZeneca’s Chief Executive Officer, Pascal Soriot, receives a British knighthood for services to UK life sciences and leadership in the global response to the COVID pandemic in the Queen’s Birthday Honours 2022.
AstraZeneca signs licence agreement with RQ Biotechnology for monoclonal antibodies against COVID-19
AstraZeneca enters into a licence agreement with RQ Biotechnology Ltd (RQ Bio) for a portfolio of early-stage monoclonal antibodies (mAbs) targeted against SARS-CoV-2, the virus that causes COVID-19.
AstraZeneca posts Q1 revenue increases, highlighting total revenue for the second quarter rose 60 per cent to $11,390m, reflecting strong growth across the company.
AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts
AstraZeneca announces plans to open a new site at the heart of the Cambridge, MA, life sciences and innovation hub.
AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been granted marketing authorisation in the European Union (EU) for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg.
AstraZeneca has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialise precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment.
AstraZeneca will today, in the presence of His Royal Highness The Prince of Wales, formally unveil The Discovery Centre (DISC) in Cambridge – a state-of-the-art research and development (R&D) facility designed to the world’s highest environmental standards and accommodating over 2,200 research scientists.
The first of many millions of doses of AstraZeneca’s COVID-19 vaccine have begun arriving in low and middle-income countries across the world through the multilateral COVAX initiative, the first steps in fulfilling the Company’s efforts to provide broad and equitable access to the vaccine.
AstraZeneca’s COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New Year.
AstraZeneca and Alexion Pharmaceuticals, Inc. have entered into a definitive agreement for AstraZeneca to acquire Alexion.
Strong immune responses were demonstrated across all age groups and boosted after a second dose.
Phase I clinical trial initiated for monoclonal antibody combination for prevention and treatment of COVID-19
The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of COVID-19, reports AstraZeneca.
AstraZeneca has concluded an agreement with the European Commission (EC) to supply up to 400 million doses of the AZD1222 COVID-19 vaccine.
AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise new antibody drug conjugate
Potential new medicine DS-1062 could redefine treatment standards in lung, breast and multiple other cancers.
AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020.
AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford’s potential new vaccine
AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford’s potential vaccine widely accessible around the world in an equitable manner.
AstraZeneca has developed valuable toolkits to help both leaders and employees effectively navigate through the COVID-19 crisis. Both toolkits are now available for download.
AstraZeneca and the University of Oxford today announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2.
AstraZeneca is joining forces with public research bodies and academic institutions as part of a UK government-led initiative to speed up the development of medicines to treat patients hospitalised with COVID-19.
AstraZeneca delivered a quarter of strong revenue and profit growth, reflecting the immense efforts of supply-chain, commercial and other colleagues around the world to get vital medicines to patients. As part of the fight, the Company has rapidly responded to the pandemic, firstly in China and then globally.
AstraZeneca will initiate a randomised, global clinical trial to assess the potential of Calquence (acalabrutinib), a blood cancer drug, in the treatment of the exaggerated immune response (cytokine storm) associated with COVID-19 infection in severely ill patients.
AstraZeneca is joining forces with government and academia with the aim of discovering novel coronavirus-neutralising antibodies.
AstraZeneca donates 9 million face masks to support healthcare workers around the world in the fight against COVID-19
AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZeneca has partnered with the World Economic Forum’s COVID Action Platform, created with the support of the World Health Organisation, to identify countries in greatest need.
St George Street Capital (SGSC), a UK registered charity, has signed a licence agreement with AstraZeneca to develop two compounds in the clinic: one for idiopathic male infertility, and the other for renal transplant rejection. The agreement enables additional compounds to be added in the future.